I have extensive experience in Trypanosoma cruzi infection and Chagas disease, covering parasite biology, host–parasite interactions, and aspects related to diagnosis and treatment. A key research interest of mine is understanding why 60–70% of infected individuals never develop clinical disease. In this context, I have investigated multiple factors potentially involved in this phenomenon. Over the past years, this interest has led me to explore vaccine strategies aimed at preventing infection, blocking disease progression, or treating chronically infected patients—who represent the majority of diagnoses and for whom effective treatment is still lacking. My work has included the identification and comparison of previously described and novel antigens, as well as the evaluation of diverse delivery platforms such as subunit vaccines with adjuvants, recombinant BCG, and baculoviruses, administered through different routes. I have also worked with various experimental models of infection, including subcutaneous and oral challenge. These studies have given me a deep understanding of the challenges and complexity inherent to vaccine development for tropical parasitic diseases, and have strengthened my motivation to promote collaborative forums that facilitate the exchange of knowledge and drive innovative solutions for those affected by these neglected conditions.